An interesting piece in Sunday's New York Times examined the rise of Dr. Steven Nissan, who is becoming increasingly visible in the movement to reform the FDA. Dr. Nissan, it's fair to say, is a controversial figure. Critics accuse him of being a little too spotlight friendly, but he's been out in front of both the Vioxx and Arcoxia trouble. Either way, the Times portrayal of him as "a Nadaresque figure" seems to speak to just how significant an issue this is. PRWeek weighed in on the need for FDA reform here.